With a label warning about weight loss that might actually help sales, Celgene Corp.’s oral phosphodieasterase-4 (PDE4) inhibitor Otezla (apremilast) was approved by the FDA on its Friday PDUFA date for adults with active psoriatic arthritis (PsA).